CCG 1423

Discontinued Product

CCG 1423 (Cat. No. 5233) has been withdrawn from sale for commercial reasons.
Description: Rho/SRF pathway inhibitor; induces intermediate mesoderm differentiation from ESCs
Chemical Name: N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)benzamide
Purity: ≥99% (HPLC)
Citations (4)

Biological Activity for CCG 1423

CCG 1423 is a Rho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells in vitro and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid, LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs.

Compound Libraries for CCG 1423

CCG 1423 is also offered as part of the Tocriscreen Stem Cell Library. Find out more about compound libraries available from Tocris.

Technical Data for CCG 1423

M. Wt 454.75
Formula C18H13ClF6N2O3
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 285986-88-1
PubChem ID 2726015
Smiles O=C(NOC(C)C(NC2=CC=C(Cl)C=C2)=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for CCG 1423

References are publications that support the biological activity of the product.

Mae et al (2010) Combination of small molecules enhances differentiation of mouse embryonic stem cells into intermediate mesoderm through BMP7-positive cells. Biochem.Biophys.Res.Commun. 393 877 PMID: 20171952

Evelyn et al (2007) CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol.Cancer Ther. 6 2249 PMID: 17699722

View Related Products by Product Action

View all Rho GTPase Inhibitors

Keywords: CCG 1423, CCG 1423 supplier, CCG1423, Rho, SRF, pathway, inhibitors, inhibits, intermediate, mesoderm, differentiation, ESC, embryonic, stem, cells, serum, response, factors, cancer, ESCs, and, iPSC, 5233, Tocris Bioscience

4 Citations for CCG 1423

Citations are publications that use Tocris products. Selected citations for CCG 1423 include:

Preet M et al (2020) Narciclasine, an isocarbostyril alkaloid, has preferential activity against primary effusion lymphoma. Sci Rep 10 5712 PMID: 32235878

Aarthi et al (2021) Inhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3. Viruses 13 PMID: 34452398

Li et al (2021) Regulation of the Muscarinic M3 Receptor by Myocardin-Related Transcription Factors. Front Physiol 12 710968 PMID: 34539433

Li et al (2021) Cell Type Dependent Suppression of Inflammatory Mediators by Myocardin Related Transcription Factors. Front Physiol 12 732564 PMID: 34671275

Reviews for CCG 1423

There are currently no reviews for this product. Be the first to review CCG 1423 and earn rewards!

Have you used CCG 1423?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review